News Search Results
Feb 11, 2026, 10:50 ET Genomics Market to Reach $97.1 Billion by 2033 Globally, at 11.5% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/connect-to-analyst/5474The pharmaceutical and biotechnology companies segment generated the highest revenue in 2023By end user, pharmaceutical and biotechnology companies accounted for the largest revenue share in 2023. These companies extensively utilize
More news about: Allied Market Research
Feb 11, 2026, 09:00 ET Decoy Therapeutics Joins Webull Corporate Connect Service Platform
https://www.webullcorp.com/About Decoy Therapeutics, Inc.Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging ML and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate
More news about: Decoy Therapeutics, Inc
Feb 11, 2026, 08:43 ET Avant Technologies Completes Rebranding with Name Change to Avaí Bio and Launch of New Website
Feb. 11, 2026 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced the completion of its corporate name
More news about: AVAI Bio Inc.
Feb 11, 2026, 08:00 ET Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases
specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug
More news about: Evogene; Systasy; LMU University Hospital Munich
Feb 11, 2026, 08:00 ET Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director
development and launch of HUMIRA across multiple indications, and has previously served on the boards of leading industry organizations including the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA)."Tim's experience developing and commercializing
More news about: Crystalys Therapeutics
Feb 11, 2026, 04:01 ET Algae Products Market Growing at 7.17% CAGR to 2031 with North America Accounting for 34.02% Revenue Share Due to Rising Veganism, Reports Mordor Intelligence
Personal Care and Feed: Expanding beyond the food sector, the algae products market size is being bolstered by high-margin applications in marine biotechnology and aquaculture. Cosmetic brands are increasingly replacing synthetic actives with algae-derived peptides and antioxidants for premium anti-aging
More news about: Mordor Intelligence Private Limited
Feb 11, 2026, 03:50 ET ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 11, 2026, 03:30 ET AmacaThera Named Life Sciences Ontario Emerging Company of the Year
this foundation, AmacaThera leverages its proprietary hydrogel platform to co-develop innovative drug delivery solutions with pharmaceutical and biotechnology partners. The platform's inherent versatility enables the creation of long-acting formulations that enhance therapeutic efficacy, improve patient
More news about: AmacaThera
Feb 11, 2026, 03:17 ET ArisGlobal Announces XDI NavaX Data Intelligence, Three New Agents, and NavaX Translation
transform compliance into a strategic advantage. ArisGlobal serves more than 300 customers globally, including many of the world's top pharmaceutical, biotechnology, and medical device companies. For more information, visit
More news about: ArisGlobal
Feb 10, 2026, 20:36 ET IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc.
purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Robbins LLP
Feb 10, 2026, 18:15 ET Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
dose of the same drugAbout Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Feb 10, 2026, 18:02 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.Details of the case: Inovio describes itself as a "biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 10, 2026, 16:05 ET Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
More news about: Nektar Therapeutics
Feb 10, 2026, 16:05 ET Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 10, 2026, 13:22 ET ISPE Announces its 2026 ISPE Aseptic Conference Keynote Speakers
for collaboration, the 2026 conference in Washington, D.C. will be the year's most influential forum for professionals across the pharmaceutical, biotechnology, and advanced therapy sectors. We've designed this program to tackle the industry's most urgent challenges and emerging opportunities head on."ISPE
More news about: ISPE
Feb 10, 2026, 11:58 ET Regenerative Medicine Market to Reach $531.7 billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research
Asia-Pacific is projected to grow at a faster pace, driven by expanding healthcare access, rising clinical trial activity, and government support for biotechnology development.Want to Explore More, Connect to our Analyst –
More news about: Allied Market Research
Feb 10, 2026, 11:17 ET Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing
spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit
More news about: Made Scientific, Inc.
Feb 10, 2026, 10:00 ET FYR Bio Appoints Barbara K. Zehentner, MBA, PhD, HCLD (ABB), as Chief Operating Officer
FYR Bio ("FYR"), a biotechnology company leveraging extracellular vesicles (EVs) to deliver AI-enabled multiomic insights from a peripheral blood sample, today announced the appointment
More news about: FYR Bio
Feb 10, 2026, 09:30 ET Greenberg Traurig Adds Employee Benefits Shareholder Lisa H. Barton in Boston Office
growth, and change."Barton's hiring also represents the latest expansion for Greenberg Traurig in Boston, a global hub for the life sciences, biotechnology, pharmaceutical, and health care industries. Since opening an office there in 1999, the team has grown to more than 100 lawyers across a wide range
More news about: Greenberg Traurig, LLP
Feb 10, 2026, 09:00 ET SickScience Launches at Ulta Beauty, Bringing Clinically-Driven Biotech Beauty to a National Retail Stage
Bridging clinical science and skincare, SickScience applies biohacking and biotechnology innovation to deliver cellular regeneration through its proprietary NX35™ Exosome Technology — a 100% vegan, plant-based system that mimics the
More news about: SickScience
Feb 10, 2026, 08:00 ET AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative
More news about: Insilico Medicine
Feb 10, 2026, 07:00 ET New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced positive results from the 36-week blinded maintenance period of the
More news about: Nektar Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01
More news about: Gyala Therapeutics
Feb 09, 2026, 21:00 ET MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's
More news about: Merry Life Biomedical Company, Ltd.